C42D client win: Teal Health lands an additional $10 million seed funding

Strong branding helps attract attention—and funding.

The future of cervical cancer screening just got a serious upgrade. Teal Health has locked in an additional $10 million in seed funding to bring the Teal Wand to market—the first FDA-approved at-home cervical cancer screening device. Led by Emerson Collective and Forerunner, with backing from Serena Ventures, Metrodora, and new investor Labcorp, this latest round pushes Teal’s total funding to $23 million.

Teal Health is gearing up to bring the Teal Wand to market—giving millions of women a simpler, more empowering way to screen for cervical cancer. With regulatory clearance on the horizon, the future of women’s health is looking a whole lot brighter.

This infusion of capital comes on the heels of two other major milestones. Teal Health recently scored a $1.68 million SBIR grant from the National Cancer Institute and also received FDA Breakthrough Device Designation. The device is now under FDA review, setting the stage for a seismic shift in women’s health.

Teal Health had come to C42D eager to give women options both for screening and staying healthy. With first-hand understanding of the invasiveness and challenges often accompanying women’s health, they sought to build a better way forward.

Together, we chose visual elements to focus on female and detract from clinical. We developed a brand identity blending symbolism with science, featuring a hummingbird-inspired mark, a teal-centric color palette, and fresh typography that resonates with both consumers and clinical audiences.

Through thoughtful design from their product development through our work together on their brand, Teal Health has continued to build momentum to bring their vision to life. We’re eager to hear more positive news this year.